Core Insights - Nordson Corporation is a global leader in precision technology solutions, specializing in equipment for dispensing adhesives, coatings, sealants, and biomaterials [1] - D.A. Davidson has set a price target of $290 for Nordson's stock, indicating a potential upside of 23.29% from its current trading price of $235.21 [1][5] Financial Performance - For the fiscal fourth quarter ending October 31, 2025, Nordson reported sales of $752 million, reflecting a 1% increase from $744 million in the previous year [2][5] - The sales growth was supported by a favorable currency translation of 2% and a 1% contribution from acquisitions, although it was partially offset by a divestiture in the medical contract manufacturing segment and a 1% decrease in organic sales [2] Stock Performance - The current stock price of Nordson is $234.35, showing a slight decrease of approximately 0.03% from the previous trading session [3] - Over the past year, the stock has experienced significant volatility, reaching a high of $251.47 and a low of $165.03, with a market capitalization of approximately $13.17 billion [4]

Group 1 - The article does not provide any relevant content regarding the company or industry [1]

Core Insights - Nordson Corporation's adjusted earnings for Q4 fiscal 2025 were $3.03 per share, exceeding the Zacks Consensus Estimate of $2.93, marking a 9% year-over-year increase [1] - Revenues for the quarter were $751.8 million, a 1% increase from the previous year, but below the consensus estimate of $769 million [2][9] - The company reported improved margins, with gross profit rising 5.1% year over year and gross margin increasing by 220 basis points to 56.3% [6][9] Quarterly Results of NDSN - Revenue breakdown showed a 4.4% decline in the Asia Pacific region to $225.5 million, while Europe saw a 5.4% increase to $195.3 million, and the Americas grew by 2.4% to $331 million [3] - Industrial Precision Solutions generated $361.7 million, down 1.5% year over year, contributing 48% to total revenues [3] - Medical and Fluid Solutions revenues were $219.5 million, up 9.6% year over year, with organic sales increasing by 7.4% [4] - Advanced Technology Solutions reported $170.6 million, down 3.6% year over year, with organic sales decreasing by 4.9% [5] Margin Profile - Cost of sales decreased by 3.9% to $328.4 million, leading to a gross profit of $423.5 million [6] - Selling and administrative expenses fell by 7% to $208.9 million, while adjusted EBITDA rose 6.1% to $255.7 million, with an operating margin of 28.5% [7] Balance Sheet & Cash Flow - At the end of Q4 fiscal 2025, cash and cash equivalents were $108.4 million, down from $116 million at the end of fiscal 2024, while long-term debt decreased to $1.68 billion from $2.10 billion [10] - The company generated net cash of $719.2 million from operating activities, a 29.3% increase year over year [11] Dividends/Share Buyback - Nordson paid out $179.1 million in dividends, an 11% increase from the previous year, and repurchased shares worth $306.4 million, significantly up from $33.3 million [12] Outlook - For fiscal 2026, Nordson projects sales between $2.83 billion and $2.95 billion, with adjusted earnings expected to be between $10.80 and $11.50 per share [13]

Financial Data and Key Metrics Changes - Sales for Q4 2025 were $752 million, up 1% from $744 million in Q4 2024. Adjusted earnings per share increased by 9% to $3.03, exceeding the midpoint of guidance [10][12][5] - Full year sales reached a record $2.8 billion, a 4% increase year-over-year, with adjusted diluted earnings per share of $10.24, also up 5% from the previous year [18][19][8] - EBITDA for Q4 was $256 million, representing a 34% margin, and for the full year, EBITDA was $900 million, or 32% of sales, marking a 6% increase year-over-year [11][19][5] Business Segment Data and Key Metrics Changes - Industrial Precision Solutions (IPS) sales decreased by 2% to $362 million in Q4, with organic sales down nearly 4%. EBITDA for IPS was $137 million, or 38% of sales [14][11] - Medical and Fluid Solutions sales increased by 10% to $220 million, with organic sales up 7%. EBITDA for this segment was $88 million, or 40% of sales, reflecting a 380 basis point improvement [15][16] - Advanced Technology Solutions (ATS) sales decreased by 4% to $171 million, with EBITDA at $43 million, or 25% of sales, down from 27% the previous year [17][11] Market Data and Key Metrics Changes - The company reported a 5% increase in backlog year-over-year, with approximately $600 million in backlog entering fiscal 2026 [27][85] - The company noted stabilization in demand for automotive and polymer processing markets, with expectations for nominal growth in these areas [25][65] Company Strategy and Development Direction - The Ascend strategy, launched five years ago, has been pivotal in achieving record sales and EBITDA, with a focus on operational excellence and strategic M&A [7][19] - The company aims for average annual revenue growth of 6%-8% and adjusted EPS growth of 10%-12% from 2025 to 2029 [24][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges and highlighted strong demand in semiconductor applications, particularly for AI and cloud computing [26][23] - The company anticipates a strong start to fiscal 2026, with guidance for sales growth of 1%-6% above fiscal 2025 levels [27][29] Other Important Information - The company generated record free cash flow of $661 million, with a cash conversion rate of 136% of net income, allowing for share repurchases and dividend increases [21][22] - The company reduced net debt by approximately $224 million, ending the year with a leverage ratio of 2.1x [20][22] Q&A Session Summary Question: Insights on ATS segment and semiconductor applications - Management noted that strength remains in semiconductor applications for AI and cloud computing, with automotive stabilizing but lower growth compared to semiconductors [33][34] Question: Margin trajectory for 2026 - Management indicated that margins in IPS and ATS are expected to be sustainable, while the medical segment may stabilize in the upper 30% range [34][35] Question: Polymer processing outlook - Management expects improvement in polymer processing order entry and backlog, indicating that the segment has troughed [39][40] Question: X-ray inspection business performance - Management highlighted that while X-ray inspection has exposure to semiconductors, it also faces challenges from automotive sectors, but new product launches are anticipated to drive growth [50][52] Question: M&A strategy and stock buyback - Management confirmed a healthy M&A pipeline while balancing share repurchases, emphasizing the importance of strategic and financial discipline [54][56] Question: Guidance rationale and market conditions - Management explained that guidance reflects a range of potential outcomes, planning for both upside and downside scenarios while feeling optimistic about the start of the year [61][62]

Financial Data and Key Metrics Changes - Sales for Q4 2025 were $752 million, up 1% from $744 million in Q4 2024, with organic sales decreasing by 1% [10] - Full year sales reached a record $2.8 billion, an increase of 4% year-over-year, with adjusted earnings per share growing 9% to $3.03 in Q4 [5][18] - EBITDA for Q4 was $256 million, representing a 34% margin, and full year EBITDA was $900 million, or 32% of sales [5][19] Business Line Data and Key Metrics Changes - Industrial Precision Solutions (IPS) sales decreased 2% to $362 million, with organic sales down nearly 4% [14] - Medical and Fluid Solutions sales increased 10% to $220 million, with organic sales up 7% [15] - Advanced Technology Solutions (ATS) sales decreased 4% to $171 million, with organic sales down approximately 5% [17] Market Data and Key Metrics Changes - The company reported a 5% increase in backlog year-over-year, with approximately $600 million in backlog entering fiscal 2026 [27] - Currency translation positively impacted sales by 2% in Q4 2025 [10] Company Strategy and Development Direction - The Ascend strategy has been pivotal in achieving record sales and EBITDA, with a focus on operational excellence and strategic M&A [7][19] - The company aims for average annual revenue growth of 6%-8% and adjusted EPS growth of 10%-12% from 2025 to 2029 [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating macroeconomic challenges and highlighted strong demand in core markets, particularly in medical and semiconductor applications [25][26] - The company anticipates returning to normal growth rates in IPS and mid-single digit organic growth in medical [25][26] Other Important Information - The company generated record cash flow of $194 million in Q4, with a cash conversion rate of 128% [5] - Share repurchases totaled approximately $300 million, and dividends were increased for the 62nd consecutive year [9][22] Q&A Session Summary Question: Insights on ATS segment and semiconductor applications - Management noted that strength remains in semiconductor applications, particularly for AI and cloud computing, while automotive demand is stabilizing [33] Question: Margin trajectory for 2026 - Management indicated that margins in IPS and ATS are expected to be sustainable, while medical margins may stabilize in the upper 30% range [34] Question: Polymer processing outlook - Management expects improvement in polymer processing order entry and backlog, indicating that the segment has troughed [40] Question: X-ray inspection business performance - Management highlighted that X-ray inspection has solid exposure to both semiconductor and automotive markets, with new product launches expected to drive growth [50] Question: M&A strategy and stock buyback - Management confirmed a robust M&A pipeline while balancing share repurchases, emphasizing the importance of strategic and financial discipline [54][56] Question: Guidance rationale and market sensitivity - Management explained that guidance reflects a range of potential outcomes, planning for both upside and downside scenarios [62]

Financial Data and Key Metrics Changes - Sales for Q4 2025 were $752 million, up 1% from $744 million in Q4 2024, with organic sales decreasing by 1% [10] - Adjusted earnings per share grew 9% year-over-year to $3.03, exceeding the midpoint of quarterly guidance [12] - Full year sales reached a record $2.8 billion, up 4% from the previous year, with adjusted diluted earnings per share of $10.24, also up 5% [18][19] Business Line Data and Key Metrics Changes - Industrial Precision Solutions (IPS) sales decreased 2% to $362 million, with organic sales down nearly 4% [13] - Medical and Fluid Solutions sales increased 10% to $220 million, with organic sales volume up 7% [14] - Advanced Technology Solutions (ATS) sales decreased 4% to $171 million, with organic sales down approximately 5% [17] Market Data and Key Metrics Changes - The company reported a 5% year-over-year increase in backlog, reaching approximately $600 million [26] - Currency translation positively impacted sales by 2% during the quarter [10] - The company noted stabilization in demand for automotive and polymer processing end markets [24] Company Strategy and Development Direction - The Ascend strategy has been pivotal in achieving record sales and EBITDA, with a focus on operational excellence and strategic M&A [6][8] - The company aims for average annual revenue growth of 6%-8% and adjusted EPS growth of 10%-12% from 2025 to 2029 [23] - The company is positioned to capitalize on profitable growth opportunities as key market headwinds have subsided [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ability to convert market opportunities into bottom-line results, anticipating a strong start to fiscal 2026 [22][26] - The company highlighted that customer destocking in the medical segment is behind them, with expectations for mid-single-digit organic growth [24] - Management acknowledged the importance of planning for both upside and downside scenarios in guidance, reflecting a cautious yet optimistic outlook [44][45] Other Important Information - The company generated record cash flow of $194 million in Q4, with a conversion rate of 128% to net income [5] - Free cash flow for the full year was a record $661 million, enabling share repurchases and dividend increases [21] - The company ended the year with a leverage ratio of 2.1 times, near the low end of its targeted range [20] Q&A Session Summary Question: Insights on ATS segment and semiconductor applications - Management noted that strength remains concentrated in semiconductor applications for AI and cloud computing, with automotive stabilizing [29][30] Question: Margin trajectory for 2026 - Management indicated that margins in IPS and ATS are expected to be sustainable, with upper 30s% margins in the medical segment being achievable [31][32] Question: Polymer processing outlook - Management stated that polymer processing has troughed, with expectations for improvement in order entry and backlog [33][52] Question: Guidance rationale - Management explained that guidance reflects a range of potential outcomes, planning for both upside and downside scenarios [44][45] Question: Backlog trends - Management confirmed that backlog is down sequentially, which is typical for Q1, but up 5% year-over-year [55]

Group 1 - The article does not provide any specific content related to a company or industry [1]

Financial Performance Highlights - Fourth quarter sales reached $752 million, a 1% increase year-over-year, inclusive of divestiture[7] - Adjusted EPS for the fourth quarter was $3.03, a 9% increase year-over-year, hitting the high-end of guidance[7] - Fiscal year 2025 saw record sales of $2.8 billion, a 4% increase year-over-year[9] - Adjusted EPS for fiscal year 2025 increased by 5% year-over-year, exceeding the midpoint of earnings targets[9] - Record EBITDA of $900 million was achieved in fiscal year 2025[9, 35] Cash Flow and Capital Allocation - Record fourth quarter Free Cash Flow (FCF) of $194 million, resulting in a strong FCF conversion of 128%[7] - Fiscal year 2025 free cash flow reached $661 million, with a conversion rate of 136%[9, 42] - Approximately $300 million was allocated to share repurchases in fiscal year 2025[9] Segment Performance - Medical and Fluid Solutions (MFS) sales increased by 10% in the fourth quarter, reaching $220 million[22] - Industrial Precision Solutions (IPS) sales were $362 million, a decrease of 2%[17] - Advanced Technology Solutions (ATS) sales were $171 million, a decrease of 4%[28] Future Outlook - Fiscal year 2026 sales are projected to grow by 1% to 6%[53] - Adjusted earnings are expected to grow by 6% to 12% in fiscal year 2026[53]

Core Insights - Nordson reported revenue of $751.82 million for the quarter ended October 2025, reflecting a year-over-year increase of 1% and an EPS of $3.03 compared to $2.78 a year ago [1] - The revenue fell short of the Zacks Consensus Estimate of $769 million, resulting in a surprise of -2.23%, while the EPS exceeded the consensus estimate of $2.93 by 3.41% [1] Financial Performance - Net Sales for Industrial Precision Solutions were $361.71 million, slightly above the average estimate of $360.05 million, but represented a year-over-year decline of 7.8% [4] - Net Sales for Advanced Technology Solutions reached $170.61 million, below the average estimate of $180.73 million, showing a year-over-year increase of 12.2% [4] - Net Sales for Medical and Fluid Solutions amounted to $219.5 million, also below the average estimate of $228.03 million, with a year-over-year increase of 9.6% [4] Stock Performance - Over the past month, Nordson's shares have returned -1.3%, contrasting with the Zacks S&P 500 composite's increase of 1.8% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Group 1: Earnings Performance - Nordson reported quarterly earnings of $3.03 per share, exceeding the Zacks Consensus Estimate of $2.93 per share, and up from $2.78 per share a year ago, representing an earnings surprise of +3.41% [1] - The company posted revenues of $751.82 million for the quarter ended October 2025, which missed the Zacks Consensus Estimate by 2.23%, compared to year-ago revenues of $744.48 million [2] Group 2: Stock Performance and Outlook - Nordson shares have increased by approximately 11.6% since the beginning of the year, while the S&P 500 has gained 16.3% [3] - The current consensus EPS estimate for the upcoming quarter is $2.25 on revenues of $649.5 million, and for the current fiscal year, it is $11.05 on revenues of $2.94 billion [7] Group 3: Industry Context - The Manufacturing - General Industrial industry, to which Nordson belongs, is currently ranked in the bottom 30% of over 250 Zacks industries, indicating potential challenges for stock performance [8]